Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by cpacon Sep 20, 2019 1:56pm

158 Views

Post# 30148914

RE:RE:RE:RE:Fear

Thanks Narmac. Good luck to you and the other investors. And to the patients that could potentially be helped by RVX's drug. The clarification on preferred shares vs debt is helpful. I have RVX on my watchlist and got the news that results would be forthcoming and just hoped to get some clarification here. Cheers.

Bullboard Posts

Silvercorp to expand into Ecuador with C$200M Adventus acquisition